RETRACTED ARTICLE: Serum sphingosine-1-phosphate levels and Sphingosine-1-Phosphate gene polymorphisms in acute respiratory distress syndrome: a multicenter prospective study

Abstract

Background: Sphingosine-1-phosphate (S1P) is a signaling phospholipid involved in pathophysiologic progression of acute respiratory distress syndrome (ARDS) through its roles in endothelial barrier function and immune modulation. We hypothesized that decreased serum S1P level is associated with the clinical outcomes of ARDS and polymorphisms in the S1P gene are associated with serum S1P levels.Methods: This multicenter prospective study includes ARDS patients and healthy blood donors as controls. Serum S1P levels were quantified using enzyme-linked immunosorbent assays. Eight tag single nucleotide polymorphisms (SNPs) in the S1P gene were detected, and their associations with S1P levels were evaluated.Results: A total of 121 ARDS patients and 100 healthy individuals were enrolled. Serum S1P levels were lower in ARDS patients than in controls (P < 0.001). Decreased S1P levels correlated with more organ dysfunction and higher Acute Physiology and Chronic Health Evaluation II scores. Changes in S1P levels in ARDS patients were associated with the clinical outcomes. The recessive model for SNP rs3743631 suggests that GG homozygote is associate with a higher risk for ARDS. The dominant model for SNP rs907045 suggests that AA or TA genotype might increase the risk for ARDS. In ARDS patients, the rs3743631 GG genotype showed lower S1P levels than those harboring AG and AA genotypes. The serum S1P levels of rs907045 AA or TA genotype patients were lower than those of TT genotype. Conclusions:Serum S1P levels are dramatically decreased in ARDS patients. Reduced S1P levels are associated with worse clinical outcomes. There is a significant association between S1P rs3743631, rs907045 polymorphisms and susceptibility of ARDS.

Lysophospholipids in Lung Inflammatory Diseases

“…However, a study using human samples showed an opposite phenomenon. Analysis of serum S1P from 121 ARDS patients and 100 healthy individuals revealed that serum S1P levels were decreased in ARDS patients [96]; however, the BAL S1P levels in patients were not measured in this study. [93].…”

Sphingolipids as Modulators of SARS-CoV-2 Infection

“…In view of this, it was suggested that S1P could be a prognostic marker to define the outcome of COVID-19. S1P serum levels were also decreased in patients suffering from acute respiratory distress syndrome (ARDS), which is a feared complication of SARS-CoV-2 (Zhao et al, 2020). The reported findings are based upon a rather small number of patients and need to be confirmed in future investigations using larger study cohorts.…”

Differential Transcriptomic Profiling Between Patients With Sepsis-Induced Ards And Sepsis Without Ards&nbsp;

“…The role of S1P and its polymorphisms in the pathogenesis of ARDS was further corroborated in a recent multicenter prospective study that determined serum levels of S1P in both ARDS patients and healthy volunteers. 62 S1P levels were dramatically decreased in ARDS. Also, lower levels of S1P correlated with greater organ dysfunction and higher Acute Physiology and Chronic Health Evaluation II scores, as well as worse ARDS-related clinical outcomes (length of stay and mortality).…”